フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph...
PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s...
SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...
Phase 1/2 dose escalation study to evaluate BriaCell’s personalized next generation immunotherapy treatment in...
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer...
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of...
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly...
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約